Skip to main content

Table 1 Baseline clinical data

From: Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case–control study

Clinical data Case group
n = 50
Control group
n = 100
Oxford classification Case group
Cases (%)
Control group
Cases (%)
At time of biopsy    Mesangial hypercellularity **   
Gender (M/F) 35/15 56/44 M0 11 (22.0%) 72 (72.0%)
Age (y) 35.8 ± 9.9 35.4 ± 10.1 M1 39 (78.0%) 28 (28.0%)
eGFR 57.3 ± 27.6** 95.7 ± 32.7 Endocapillary hypercellularity   
sCr (mg/dl) 1.4 (0.8–4.3)** 0.9 (0.5–2.1) E0 14 (28.0%) 32 (32.0%)
UA (mg/dl) 8.0 (1.9–15.3)** 5.7 (2.3–12.9) E1 36 (72.0%) 68 (68.0%)
Hb (g/dl) 12.2 ± 2.0* 12.9 ± 1.8 Segmental Glomerulosclerosis*   
Alb (g/dl) 3.5 ± 0.8* 3.9 ± 0.6 S0 12 (24.0%) 52 (52.0%)
TC (mg/dl) 207.7 (111.5–392.3)* 184.6 (100.0–369.2) S1 38 (76.0%) 48 (48.0%)
Proteinuria (g/day) 2.9 (0.1–8.3)** 0.8 (0–9.9) Tubular atrophy/Interstitial fibrosis**   
Hypertension 31 (62.0%)* 47 (47.0%) T0 16 (32.0%) 86 (86.0%)
Macro-hematuria 2 (4.0%)* 18 (18.0%) T1 26 (52.0%) 11 (11.0%)
    T2 8 (16.0%) 3 (3.0%)
  1. eGFR estimated glomerular filtration rate (ml · min-1 · (1.73 m2)-1), sCr serum creatinine, UA uric acid, Hb hemoglobin, Alb serum albumin, TC total cholesterol
  2. *P < 0.05; **P < 0.001